Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
5.02
Industry P/E
--
Debt to Equity
-1.08
ROE
-7.23 %
ROCE
-3817.49 %
Div. Yield
0 %
Book Value
--
EPS
-0.75
CFO
$-169.81 Mln
EBITDA
$-194.42 Mln
Net Profit
$-177.61 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aspira Women's Health (AWH)
| -96.17 | -80.71 | -94.77 | -99.22 | -87.92 | -72.53 | -49.99 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|
|
Aspira Women's Health (AWH)
| -18.22 | -73.62 | 728.40 | 170.00 | -84.30 | 103.16 |
|
S&P Small-Cap 600
| 13.89 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.48 | 150.62 | -- | -37.31 | |
| 1.21 | 119.89 | -- | 89.97 | |
| 37.77 | 3,240.56 | -- | -19.2 |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum... test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas. Address: Building III, Austin, TX, United States, 78738 Read more
CEO & Director
Ms. Nicole Sandford C.P.A.
CEO & Director
Ms. Nicole Sandford C.P.A.
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aspira Women's Health Inc (AWH) stood at $ 5 Mln as on 31-Dec-24
The share price of Aspira Women's Health Inc (AWH) is $0.03 (NASDAQ) as of 17-Apr-2025 09:30 EDT. Aspira Women's Health Inc (AWH) has given a return of -87.92% in the last 3 years.
Aspira Women's Health Inc (AWH) has a market capitalisation of $ 3 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aspira Women's Health Inc (AWH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aspira Women's Health Inc (AWH) and enter the required number of quantities and click on buy to purchase the shares of Aspira Women's Health Inc (AWH).
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas. Address: Building III, Austin, TX, United States, 78738
The CEO & director of Ms. Nicole Sandford C.P.A.. is Aspira Women's Health Inc (AWH), and CFO & Sr. VP is Ms. Nicole Sandford C.P.A..
There is no promoter pledging in Aspira Women's Health Inc (AWH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
408
|
|
|
31
|
|
|
21
|
|
|
408
|
| Aspira Women's Health Inc. (AWH) | Ratios |
|---|---|
|
Return on equity(%)
|
531.41
|
|
Operating margin(%)
|
-177.28
|
|
Net Margin(%)
|
-142.61
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aspira Women's Health Inc (AWH) was $0 Mln.
$-0.06
(
